A safe new Alzheimer's drug has been developed. It is called Blarcamesine.
For the past few years, the FDA has been reluctant to accept the application for approval of this new drug, Blarcamesine.

Blarcamesine has demonstrated tremendous effectiveness in slowing down the cognitive decline of those suffering Alzheimer's Disease.

In other words, the drug allows your mother to remember who you are for a longer period of time. Years longer, it appears.

The drug demonstrated its effectiveness in a 48-week trial in which those patients who took the drug demonstrated a 36% slower decline in their ability to remember, reason, and understand. This is based on a test known as the ADAS-Cog13.

For those people with the wild-type of the Sigmar1 gene, the drug slowed cognitive decline by over 49%. About 70% of the human population have the wild-type of the Sigmar1 gene. In this scenario, if it takes ten years for your Alzheimer's-afflicted mother to forget who you are, it will now take 20 years. You get 10 extra years.

On another test, which is known as the CDR-SB, the drug Blarcamesine slowed cognitive and behavioral decline by 27%. The CDR-SB not only measures the thinking and memory skills of patients, but also measures how they carry on their daily lives. How do they eat, dress, go to the bathroom?

The 27% slowing down of cognitive-behavioral decline matched the performance of another drug called Lecanemab, which was approved by the FDA two years ago.

While Blarcamesine is safe, Lecanemab can cause brain bleeding, resulting in brain damage and death. It requires regular brain MRIs, as well as intravenous infusions every few weeks.

Another benefit of Blarcamesine is that it prevents brain loss. People suffering from Alzheimer's Disease lose brain cells by the billions. Their brains literally shrink. Blarcamesine slows down this brain shrinkage, a condition that is impossible to come back from.

While Blarcamesine seems obviously superior to Lecanemab, there is one issue that the FDA may have been stuck on. Blarcamesine did not prove that it slowed behavioral decline as measured by a test known as the ADCS-ADL. This test involves interviewing caregivers about how well the patient is eating, dressing, taking themselves to the bathroom, etc.

Some outdated guidelines of the FDA stated that an Alzheimer's drug must prove effectiveness in slowing decline in both cognition and behavior. These guidelines have recently been revised to make them less stringent.

The FDA may be ignoring the fact that Blarcamesine demonstrated effectiveness in the cognitive and behavioral realms through its performance on the CDR-SB test. The FDA may be focusing solely on the ADCS-ADL and blocking/delaying Blarcamesine based on its lack of effectiveness on this purely behavioral test.

The children of Alzheimer's patients DO NOT CARE if a drug "only" helps them with their memory and reasoning.

We WANT OUR LOVED ONES TO TRY THE DRUG. EVEN IF IT ONLY HELPS THEM REMEMBER AND THINK.

We want Blarcamesine approved this year. 2025. ASAP.

President Trump, you are ushering in common sense reforms throughout the government. Please bring common sense to the FDA. Allow a safe drug to be approved for a fatal, devastating disease that has no safe treatments.

Tell the FDA to approve Blarcamesine in 2025, so we can help our Alzheimer's-afflicted loved ones NOW.

Please, President Trump; please, FDA, allow us to access this drug, so that our parents and grandparents can remember who we are.

And even more importantly, to remember who they are.